Cannara Biotech

Cannara Biotech Forward P/E

The Forward P/E Ratio of Cannara Biotech (LOVE.V) as of Nov 4, 2026 is 13.18. In the previous year, Forward P/E Ratio was 26.78 — a change of -50.76% (lower).

Forward P/E

13.18

YoY

-50.76%

Last updated:

Forward P/E Ratio of Cannara Biotech is 2025 13.18 . Forward P/E Ratio of Cannara Biotech was 2024 26.78 . It decreases by -50.76% lower compared to the previous year.

The Cannara Biotech Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2018
-81.60 CAD
Jan 1, 2019
-14.00 CAD
Jan 1, 2020
-13.81 CAD
Jan 1, 2021
-112.82 CAD
Jan 1, 2022
74.78 CAD
Jan 1, 2023
24.82 CAD
Jan 1, 2024
26.78 CAD
Jan 1, 2025
13.18 CAD
The Cannara Biotech Forward P/E history
YEARForward P/EYoY
13.18-50.76%
26.78+7.87%
24.82-66.81%
74.78-166.28%
-112.82+716.85%
-13.81-1.34%
-14.00-82.84%
-81.60—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cannara Biotech Stock analysis

What does Cannara Biotech do? Cannara Biotech, Inc. generates revenue through its Cannabis operations segment, which includes the cultivation, processing, and sale of dried cannabis and cannabis derivatives for the Canadian market. The company's brand portfolio features Tribal, Nugz, and Orchid CBD, with Orchid CBD specifically targeting the wellness market as a premium CBD-dominant product. The Real estate operations segment involves the management of Farnham and Valleyfield properties, contributing to the company's overall revenue streams. The firm's two mega facilities in Quebec, spanning over 1,650,000 square feet, enable annualized cultivation output of 100,000 kilograms, supporting both product lines and real estate activities. The primary buyers for Cannara's cannabis products are Canadian consumers and businesses within the regulated cannabis market. Tribal and Nugz are positioned as premium cannabis brands, while Orchid CBD serves the wellness segment with its CBD-dominant offerings. Real estate operations focus on leasing and managing the Farnham and Valleyfield buildings, which are part of the company's owned properties. The company's subsidiary structure, including Cannara Biotech (Quebec) Inc. and Cannara Biotech (Valleyfield) Inc.), supports both operational segments without external partnerships or third-party dependencies. Cannara Biotech's revenue model combines direct sales of cannabis products under its brand portfolio with property management income from its real estate holdings. The company's two facilities in Quebec provide the scale necessary for both cultivation and real estate operations, with the Cannabis operations segment driving most of the product-related sales. The Real estate operations segment complements this by generating steady income from the Farnham and Valleyfield properties, which are integral to the company's asset base. Cannara Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cannara Biotech stock

Forward P/E Ratio of Cannara Biotech is 13.18 in 2025.

Forward P/E Ratio of Cannara Biotech changed from 26.78 to 13.18, representing a -50.76% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio Cannara Biotech since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's Cannara Biotech with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Cannara Biotech

All Key Metrics — Cannara Biotech